Filing Flows › Jazz Pharmaceuticals (JAZZ) › Q3 2026 › vs Q2 2026
Jazz Pharmaceuticals (JAZZ) Q3 2026 vs Q2 2026 (quarter over quarter)
Jazz Pharmaceuticals's revenue rose $34.7M (+3%) from $1.2B in Q2 2026 to $1.2B in Q3 2026.
Jazz Pharmaceuticals, Q3 2026: revenue $1.2B (+10% year over year), operating margin -33.3%, net loss $483M, operating cash flow $506M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 39.4% | 32.9% | +6.5 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $34.7M | +3% |
| Net loss | $483M | −$193M | $676M | — |
| Costs & expenses | $1.7B | $1.2B | $518M | +43% |
| Operating costs | $1.7B | $960M | $696M | +73% |
| Interest & other, net | $45.5M | $37.2M | $8.3M | +22% |
| Income tax | $24.5M | $18.1M | $6.4M | +35% |
| Research & development | $212M | $208M | $4.4M | +2% |
| SG&A | $408M | $389M | $18.7M | +5% |
| Other operating costs | $1.0B | $363M | $673M | +185% |
| Operating cash sources | $990M | $223M | $767M | +344% |
| Depreciation & amortization | $179M | $179M | −$200K | -0.1% |
| Share-based compensation | $77.2M | $73.3M | $3.9M | +5% |
| Working capital & other | $733M | −$29.5M | $763M | — |
| Net loss absorbed | $483M | −$193M | $676M | — |
| Operating cash flow | $506M | $416M | $90.4M | +22% |
| Free cash flow (OCF − capex) | $490M | $398M | $92.3M | +23% |
| Capital expenditures | $16.2M | $18.1M | −$1.9M | -10% |
Questions
How much did Jazz Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Jazz Pharmaceuticals's revenue rose $34.7M (+3%) from $1.2B in Q2 2026 to $1.2B in Q3 2026.